Prostate Cancer

Arpita Desai, MD, medical oncologist, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the rationale for testing MRI functional imaging for bone metastases in men with castration-resistant prostate cancer.

In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.

The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Historically, urologists have been the primary caretakers for men with localized prostate cancer, which is the most prevalent solid tumor in men over 50 years of age and the second-leading cause of cancer-specific mortality in the United States today.

The 5α-reductase inhibitor finasteride (Proscar), an agent commonly used to treat lower urinary tract problems and baldness in men, was found to be safe and effective in reducing the risk of prostate cancer.

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination therapy for patients with newly diagnosed metastatic prostate cancer.

Stereotactic body radiation therapy has been found to be a safe and effective option for patients with low- and intermediate-risk prostate cancer.

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses sequencing in metastatic castration-resistant prostate cancer (mCRPC).

The novel targeted radiation therapy lutetium-177 PSMA-617 showed strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer.

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses ways to improve stratification of patients with prostate cancer.

Advocates for sipuleucel-T point out that the public has become more aware of and interested in immunotherapy now, and they believe the product has the potential to benefit a larger group of patients.

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses standard approaches to radiation therapy in prostate cancer.

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses factors that can lead to disparity in access to prostate cancer therapy.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses the importance of understanding the molecular subtypes of prostate cancer.

Apalutamide (Erleada) in combination with androgen deprivation therapy was found to significantly improve radiographic progression-free survival and overall survival versus placebo in patients with metastatic castration-sensitive prostate cancer.

Tanya B. Dorff, MD, discusses landmark approvals in nonmetastatic castration-resistant prostate cancer and anticipated developments in the space.

Tanya B. Dorff, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, head, Genitourinary Cancers Program, City of Hope, discusses choosing between therapies in nonmetastatic castration-resistant prostate cancer.

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses a study aiming to refine racial risk stratification in prostate cancer.

Evan Y. Yu, MD, discusses the available options for patients with metastatic castration-naïve prostate cancer.

Harsha Ranganath, MD, discusses the current and future treatment of patients with nonmetastatic castration-resistant prostate cancer.

Holger L. Gieschen, MD, discusses the role of radiation therapy in prostate cancer and ongoing efforts to further refine this strategy.

An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen use.

Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.

Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.

Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.

Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.